

Attorney Docket No.: INEX.P-003-3

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Semple et al.
Serial No.: 10/658,947
Confirmation:
Filed: September 9, 2003
Title: High Efficiency Encapsulation of Charged Therapeutic Agents in Lipid Vesicles

SUBMISSION OF INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants request that the references listed on Substitute Form PTO-1449, which is enclosed, be made of record in the Patent Office file relating to the above-captioned application. Copies of the references are provided herewith.

Applicants advise the Examiner that US Patent Application No. 08/657,753 and US Provisional Application No. 60/073,852 may be of interest.

No fee is believed to be due with this paper as we have not received an action on the merits. The Commissioner is authorized to charge any fees which may be due to Deposit Account Number 15-0610.

Respectfully submitted,

OPPEDAHL & LARSON LLP

Marina T. Larson, PhD , Reg. No. 32,038
P.O. Box 5068
Dillon, CO 80435-5068
970-468-6600

CERTIFICATE OF MAILING UNDER 37 CFR §1.8(a)


I hereby certify that this paper and the attachments named herein are being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on _____

Feb 11, 2004

2-11-04

Date of Signature

Lori South



PTO/SB/08A (06-03)

Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|---------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/658,947 |
| | | | | Filing Date | 9/9/2003 |
| | | | | First Named Inventor | Sample et al. |
| | | | | Art Unit | |
| | | | | Examiner Name | |
| Sheet | 1 | of | 5 | Attorney Docket Number | INEX.P-003-3 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | | US- 3,993,754 | 11/23/1976 | Rahman et al. | |
| | | US- 4,145,410 | 3/20/1979 | Sears | |
| | | US- 4,224,179 | 9/23/1980 | Schneider | |
| | | US- 4,235,871 | 11/25/1980 | Papahadjopoulos et al. | |
| | | US- 4,401,796 | 8/30/1983 | Itakura | |
| | | US- 4,458,066 | 7/3/1984 | Caruthers et al. | |
| | | US- 4,500,707 | 2/19/1985 | Caruthers et al. | |
| | | US- 4,522,803 | 6/11/1985 | Lenk et al. | |
| | | US- 4,588,578 | 5/13/1986 | Fountain et al. | |
| | | US- 5,013,556 | 5/7/1991 | Woodle et al. | |
| | | US- 5,208,036 | 5/4/1993 | Eppstein et al. | |
| | | US- 5,264,618 | 11/23/1993 | Felgner et al. | |
| | | US- 5,264,423 | 11/23/1993 | Cohen et al. | |
| | | US- 5,276,019 | 1/4/1994 | Cohen et al. | |
| | | US- 5,279,833 | 1/18/1994 | Rose | |
| | | US- 5,283,185 | 2/1/1994 | Epan et al. | |
| | | US- 5,286,634 | 2/15/1994 | Stadler et al. | |
| | | US- 5,356,633 | 10/18/1994 | Woodle et al. | |
| | | US- ,5532,130 | 7/2/1996 | Alul | |
| | | US- 5,552,155 | 9/3/1996 | Bailey et al. | |
| | | US- 5,665,710 | 9/9/1997 | Rahman et al. | |
| | | US- 5,885,613 | 3/23/1999 | Holland et al. | |
| | | US- 5,976,567 | 11/2/1999 | Wheeler et al. | |


| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|--|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | - | WO 00/62813 A2 | 10/26/2000 | The University of British Columbia | | |
| | - | WO 96/10391 A1 | 4/11/1996 | The University of British Columbia | | |
| | - | WO 96/10392 A1 | 4/11/1996 | The University of British Columbia | | |
| | - | WO 96/40964 A2 | 12/19/1996 | Inex Pharmaceuticals Corporation | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of US PTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B (06-03)

Approved for use through 06/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | |
|---|---|--------------------------|---------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/658,947 |
| | | Filing Date | 9/9/2003 |
| | | First Named Inventor | Semple et al. |
| | | Art Unit | |
| | | Examiner Name | |
| Sheet | 2 | of | 5 |
| | | Attorney Docket Number | INEX.P-003-3 |


| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | - | AGRAWAL, Antisense oligonucleotides: towards clinical trials, Trends in Biotech, 1996 , Page(s) 376-387, Volume 14 | |
| | | ATKINSON ET AL., Solid-phase Synthesis of Oligodeoxyribonucleotides by the Phosphite-triester Method, Oligonucleotide Synthesis: A Practical Approach, 1984, Page(s) 35-81, Volume 3 | |
| | | BAILEY ET AL., Modulation of Membrane Fusion by Asymmetric Transbilayer Distributions of Amino Lipids, Biochem., 1994, Page(s) 12573-12580, Volume 33, Number 42 | |
| | | BEAUCAGE ET AL., Deoxynucleoside Phosphoramidites--A New Class of Key Intermediates for Deoxypolynucleotide Synthesis, Tetrahedron Letters, 1981, Page(s) 1859-1862, Volume 22, Number 20 | |
| | | BEHR, Synthetic Gene-Transfer Vectors, Acc. Chem. Res., 1993, Page(s) 274-278, Volume 26 | |
| | | BENNETT ET AL., Cationic Lipids Enhance Cellular Uptake and Activity of Phosphorothioate Antisense Oligonucleotides, Molecular Pharmacology, 1992, Page(s) 1023-1033, Volume 41, Number 6 | |
| | | BENNETT, Intracellular Delivery of Oligonucleotides with Cationic Liposomes, CRC Press, 1995, Page(s) 223-322, Number 14 | |
| | | BRIGHAM ET AL., Rapid Communication: In vivo Transfection of Murine Lungs with a Functioning Prokaryotic Gene Using a Liposome Vehicle, The American Journal of the Medical Sciences, 1989, Page(s) 278-281, Volume 298, Number 4 | |
| | | CARUTHERS ET AL., New Methods for Synthesizing Deoxyoligonucleotides, Genetic Engineering, 1982, Page(s) 1-17, Volume 4 | |
| | | CULVER K. W., Gene Therapy: A Handbook for Physicians, Mary Ann Liebert, Inc., Publishers, New York, 1994, pp. 33-41 | |
| | | DEWHIRST ET AL., Extravasation of Stealth Liposomes into Tumors: Direct Measurement of Accumulation and Vascular Permeability Using a Skin Flap Window Chamber, Eds. Lasic, 1995 , Page(s) 127-137, Number 12 | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Approved for use through 06/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|---------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/658,947 |
| | | | | Filing Date | 9/9/2003 |
| | | | | First Named Inventor | Semple et al. |
| | | | | Art Unit | |
| | | | | Examiner Name | |
| Sheet | 3 | of | 5 | Attorney Docket Number | INEX.P-003-3 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | FISKE ET AL., The Colorimetric Determination of Phosphorous, J. Biol. Chem., 1925, Page(s) 375-400, Volume 66, Number 2 | |
| | | FROEHLER ET AL., Synthesis of DNA via deoxynucleoside H-phosphonate intermediates, Nucleic Acids Research, 1986, Page(s) 5399-5407, Volume 14, Number 13 | |
| | | GALBRAITH ET AL., Complement Activation and Hemodynamic Changes Following Intravenous Administration of Phosphorothioate Oligonucleotides, Antisense Research and Development, 1994, Page(s) 201-206, Volume 4, Number 3 | |
| | | GUO ET AL., Steric Stabilization of Fusogenic Liposomes by a Low-pH Sensitive PEG-Diortho Ester-Lipid Conjugate, Bioconjugate Chem., 2001, Page(s) 291-300, Volume 12 | |
| | | HYDE ET AL., Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy, Nature, 1993, Page(s) 250-256, Volume 362, Number 6417 | |
| | | JONES, Preparation of Protected Deoxyribonucleosides, Oligonucleotide Synthesis: A Practical Approach, 1984, Page(s) 23-34, Number 2 | |
| | | KUNKEL ET AL., Duchenne/Becker muscular dystrophy: A short overview of the gene, the protein, and current diagnostics, British Medical Bulletin, 1989, Page(s) 630-643, Volume 45, Number 3 | |
| | | MANNINO ET AL., Liposome Mediated Gene Transfer, Biotechniques, 1988, Page(s) 682-690, Volume 6, Number 7 | |
| | | MATTEUCCI ET AL., Synthesis of Deoxyoligonucleotides on a Polymer Support, J. Am. Chem. Soc., 1981 Page(s) 3185-3191, Volume 103 | |
| | | NICOLAU ET AL., Liposomes as Carriers of DNA, Crit. Rev. Ther. Drug Carrier Syst., Volume 6, Issue 3, 1989, pp. 239-271 | |
| | | SINHA ET AL., β -Cyanoethyl N,N-Dialkylamino/N-Morpholinomonocho Phosphoamidites, New Phosphitylating Agents Facilitating Ease of Deprotection and Work-up of Synthesized Oligonucleotides, Tetrahedron Letters, 1983, Page(s) 5843-5846, Volume 24, Number 52 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|---|--------------------------|---------------|------------------------|--------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/658,947 | | |
| | | Filing Date | 9/9/2003 | | |
| | | First Named Inventor | Sample et al. | | |
| | | Art Unit | | | |
| | | Examiner Name | | | |
| Sheet | 4 | of | 5 | Attorney Docket Number | INEX.P-003-3 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | SINHA ET AL., Polymer support oligonucleotide synthesis XVIII: use of β -cyanoethyl-N,N-dialkylamino-/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product, Nucleic Acids Research, 1984, Page(s) 4539-4557, Volume 12, Number 11 | |
| | | SPROAT ET AL., Solid-phase Synthesis of Oligodeoxyribonucleotides by the Phosphotriester Method, Oligonucleotide Synthesis: A Practical Approach, 1984, Page(s) 83-115, Volume 4 | |
| | | STEIN ET AL., Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?, Science, 1993, Page(s) 1004-1012, Volume 261, Number 5124 | |
| | | STEPKOWSKI ET AL., Blocking of Heart Allograft Rejection by Intercellular Adhesion Molecule-1 Antisense Oligonucleotides Alone or in Combination with Other Immunosuppressive Modalities, J. Immunol., 1994, Page(s) 5336-5346, Volume 153, Number 11 | |
| | | STRAUBINGER ET AL., Liposomes as Carriers for Intracellular Delivery of Nucleic Acids, Methods in Enzymology, 1983, Page(s) 512-527, Volume 101 | |
| | | THIERRY ET AL., Liposomal Delivery as a New Approach to Transport Antisense Oligonucleotides, Gene Regulation: Biology of Antisense RNA and DNA, 1992, Page(s) 147-161 | |
| | | UHLMANN ET AL., Antisense: Chemical Modifications, Encyclopedia of Cancer, 1997, Page(s) 64-81, Volume X | |
| | | VLASSOV ET AL., Transport of oligonucleotides across natural and model membranes, Biochimica et Biophysica Acta, 1994, Page(s) 95-108, Volume 1197 | |
| | | WU ET AL., Increased Microvascular Permeability Contributes to Preferential Accumulation of Stealth Liposomes in Tumor Tissue, Cancer Research, 1993, Page(s) 3765-3770, Volume 53, Number 16 | |
| | | YUDA ET AL., Prolongation of Liposome Circulation Time by Various Derivatives of Polyethyleneglycols, Biol Pharm. Bull., 1996, Pages 1347-1351, Volume 19, No. 10 | |
| | | ZELPHATI ET AL., Inhibition of HIV-1 Replication in Cultured Cells with Antisense Oligonucleotides Encapsulated in Immunoliposomes, Antisense Research and Development, 1993, Page(s) 323-338, Volume 3 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | |
|---|---|--------------------------|---------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/658,947 |
| | | Filing Date | 9/9/2003 |
| | | First Named Inventor | Sample et al. |
| | | Art Unit | |
| | | Examiner Name | |
| | | Attorney Docket Number | INEX.P-003-3 |
| Sheet | 5 | of | 5 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | ZELPHATI ET AL., Liposomes as a carrier for intracellular delivery of antisense oligonucleotides: a real or magic bullet?, Journal of Controlled Release, 1996, Volume 41, Pages 99-119 | |
| | | ZELPHATI ET AL., Cationic Liposomes as an Oligonucleotide Carrier: Mechanism of Action, Journal of Liposome Research, 1997, Volume 7, No. 1, Pages 31-49 | |
| | | ZHU ET AL., Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice, Science, 1993, Volume 261, Pages 209-211 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.